Drugs that contain Vortioxetine Hydrobromide
1. Drug name - TRINTELLIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7144884 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Jun, 2026
(3 years from now) | |
| US8722684 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2031
(8 years from now) | |
| CN101636161A | TAKEDA PHARMS USA | 1-[2-(2,4-Dimethylphenylsulphanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition |
Apr, 2015
(7 years ago) | |
| CN1561336A | TAKEDA PHARMS USA | Phenylpiperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| CN1319958C | TAKEDA PHARMS USA | Phenylpiperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| CN102614179A | TAKEDA PHARMS USA | Combination For Medicament For Treating Cognitive Impairment The Combination Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A Activity Of 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine |
Jun, 2027
(4 years from now) | |
| CN102617513B | TAKEDA PHARMS USA | As A Medicament For Treating Cognitive Impairment, A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity Of 1 - (2 - (2, 4 - - Dimethyl Phenyl Sulfur Alkyl) - Phenyl] Piperazine |
Jun, 2027
(4 years from now) | |
| CN102617513A | TAKEDA PHARMS USA | 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine Of Compound As A Medicament For Treating Cognitive Impairment, Comprising Combined Activity Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A |
Jun, 2027
(4 years from now) | |
| CN101472906B | TAKEDA PHARMS USA | Combination For Medicament For Treating Cognitive Impairment The Combination Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A Activity Of 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine |
Jun, 2027
(4 years from now) | |
| CN101472906A | TAKEDA PHARMS USA | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment |
Jun, 2027
(4 years from now) | |
| CN102614179B | TAKEDA PHARMS USA | As A Medicament For Treating Cognitive Impairment, A Compound Having Serotonin Reuptake Activity Of Binding, 5-Ht3 And 5-Ht1A Of 1 - [2 - (2, 4-Dimethyl Phenyl Sulfanyl) - Phenyl] Piperazine |
Jun, 2027
(4 years from now) | |
| IN200800326P4 | TAKEDA PHARMS USA | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| IN227963B | TAKEDA PHARMS USA | Pharmaceutical Composition Comprising Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| IN257628B | TAKEDA PHARMS USA | Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| IN200400910P4 | TAKEDA PHARMS USA | Pharmaceutical Composition Comprising Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| IN322445B | TAKEDA PHARMS USA | A Process For The Preparation Of 1-[2- (2,4- Dimethylphenylsulfa Nyl)Phenyl] Piperazine |
Jun, 2027
(4 years from now) | |
| IN200806886P4 | TAKEDA PHARMS USA | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake,5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment |
Jun, 2027
(4 years from now) | |
| EP1749818A2 | TAKEDA PHARMS USA | Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| EP1749818B1 | TAKEDA PHARMS USA | Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| EP1749818A3 | TAKEDA PHARMS USA | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2022
(2 days from now) | |
| EP2439201B1 | TAKEDA PHARMS USA | Compounds With Combined Sert, 5-Ht3 And 5-Ht1A Activity |
Jun, 2027
(4 years from now) | |
| EP2044043B1 | TAKEDA PHARMS USA | 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine Hydrobromide As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment |
Jun, 2027
(4 years from now) | |
| EP2044043A1 | TAKEDA PHARMS USA | 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment |
Jun, 2027
(4 years from now) | |
| EP2439201A1 | TAKEDA PHARMS USA | Compounds With Combined Sert, 5-Ht3 And 5-Ht1A Activity |
Jun, 2027
(4 years from now) | |
| EP2044043B2 | TAKEDA PHARMS USA | 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine Hydrobromide As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment |
Jun, 2027
(4 years from now) | |
| EP1436271B1 | TAKEDA PHARMS USA | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2027
(5 years from now) | |
| EP1436271A1 | TAKEDA PHARMS USA | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2027
(5 years from now) | |
| EP1436271B3 | TAKEDA PHARMS USA | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors |
Oct, 2027
(5 years from now) | |
| EP2142193A2 | TAKEDA PHARMS USA | 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition |
Mar, 2028
(5 years from now) | |
| EP2142193B1 | TAKEDA PHARMS USA | 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition |
Mar, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8476279 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Oct, 2022
(2 days from now) | |
| US9861630 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9125908 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9125910 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9125909 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9227946 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US8969355 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9278096 | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Mar, 2032
(9 years from now) | |
Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 10MG BASE | TABLET;ORAL | Prescription |
| EQ 15MG BASE | TABLET;ORAL | Discontinued |
| EQ 20MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.